MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/myc.13591

Медицинская библиотека · Mycoses · 2023

Treatment of pulmonary mucormycosis with adjunctive nebulized amphotericin B (MUCONAB trial): Results of an open-label randomized controlled trial.

Muthu Valliappan, Gogineni Ratnakara Rao, Agarwal Ritesh, Prasad Kuruswamy Thurai, Sehgal Inderpaul Singh, Dhooria Sahajal, Aggarwal Ashutosh N, Rudramurthy Shivaprakash Mandya, Singh Harkant, Garg Mandeep, Chakrabarti Arunaloke

Рандомизированное исследованиеСтатьяПеревод в очереди

Аннотация

BACKGROUND

The role of nebulized amphotericin B (NAB) in managing pulmonary mucormycosis (PM) is unknown.

METHODS

In this open-label trial, we randomized PM subjects to receive either intravenous liposomal amphotericin B (control arm, 3-5 mg/kg/day) alone or along with nebulized amphotericin B deoxycholate (NAB, 10 mg twice a day, every alternate day). The primary outcomes were: (1) overall response ('success' [complete or partial response] or 'failure' [stable disease, progressive disease, or death]) at 6 weeks; and (2) the proportion of subjects with adverse events (AE). The key secondary outcome was 90-day mortality. We performed a modified intention-to-treat (mITT) analysis where we included only subjects receiving at least a single dose of NAB.

RESULTS

Fifteen and 17 subjects were randomized to the control and NAB arms; two died before the first dose of NAB. Finally, we included 30 subjects (15 in each arm; mean age 49.8 years; 80% men) for the mITT analysis. Diabetes mellitus (n = 27; 16/27 were COVID-19-associated PM) was the most common predisposing factor. The overall treatment success was not significantly different between the control and the NAB arms (71.4% vs. 53.3%; p = .45). Twenty-nine subjects experienced any AE, but none discontinued treatment. The 90-day mortality was not significantly different between the control (28.6%) and NAB arm (53.3%; p = .26).

CONCLUSION

Adjunctive NAB was safe but did not improve overall response at 6 weeks. A different dosing schedule or nebulized liposomal amphotericin B may still need evaluation. More research is needed to explore other treatment options for PM.

Для цитирования: Muthu Valliappan, Gogineni Ratnakara Rao, Agarwal Ritesh, Prasad Kuruswamy Thurai, Sehgal Inderpaul Singh, Dhooria Sahajal, Aggarwal Ashutosh N, Rudramurthy Shivaprakash Mandya, Singh Harkant, Garg Mandeep, Chakrabarti Arunaloke. Treatment of pulmonary mucormycosis with adjunctive nebulized amphotericin B (MUCONAB trial): Results of an open-label randomized controlled trial.. Mycoses. 2023. DOI: 10.1111/myc.13591.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.